Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 5, 2016
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002)A Tsuburaya, N Sugimoto, H Imamura, et al.
ESMO Open|May 27, 2026
Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathwayY Matsubara, M Wakabayashi, W Okamoto, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in <i>BRAF</i> V600E-mutated metastatic colorectal cancer: GI-SCREEN <i>post-hoc</i> analysisM Imai, Y Nakamura, T Denda, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 23, 2010
A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle modelK Taniguchi, K Katagiri, H Kashiwagi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2015
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)M-H Ryu, E Baba, K H Lee, et al.
ESMO Open|October 10, 2025
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)T Masuishi, H Taniguchi, D Kotani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trialsT Yoshino, J M Cleary, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 6